Clinigen splashes £150M for unlicensed medicines company Quantum Pharma

Clinigen is currently worth more than $1 billion in market value, while Quantum Pharma is worth less than $100 million.

Looking to boost its drug offerings, U.K. CRO Clinigen has paid £150.3 million (around $200 million) to buy out Quantum Pharma.

The CRO will gain specialty pharma group Quantum Pharma as it looks to create a new division to supply healthcare providers with so-called unlicensed medicines, i.e., those still in trials and not yet approved.

CEO Shaun Chilton told Reuters in an interview: “(Quantum) introduces an unlicensed medicine in the initial stages to cope with an unmet need and it converts it into a licensed medicine. That unlicensed-to-licensed piece acts as a bridge between two of our business operations: our unlicensed medicines division and our commercial medicines division.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Clinigen is currently worth more than $1 billion in market value, while Quantum Pharma is worth less than $100 million.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.